Seattle Genetics, Inc.  

(Public, NASDAQ:SGEN)   Watch this stock  
Find more results for sgen
45.30
+1.32 (3.00%)
Aug 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 43.71 - 45.32
52 week 26.02 - 49.66
Open 44.14
Vol / Avg. 652,569.00/684,411.00
Mkt cap 6.56B
P/E     -
Div/yield     -
EPS -0.76
Shares 140.52M
Beta 1.74
Inst. own 99%
Oct 27, 2016
Q3 2016 Seattle Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 7, 2016
Seattle Genetics Inc at Credit Suisse Antibody Day Add to calendar
Jul 26, 2016
Q2 2016 Seattle Genetics Inc Earnings Call
Jul 26, 2016
Q2 2016 Seattle Genetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -34.32% -35.77%
Operating margin -35.05% -35.91%
EBITD margin - -31.60%
Return on average assets -15.07% -17.80%
Return on average equity -19.42% -26.87%
Employees 759 -
CDP Score - -

Address

21823 30th Dr SE
BOTHELL, WA 98021-3907
United States - Map
+1-425-5274000 (Phone)
+1-425-5274001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company's pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.

Officers and directors

Clay B. Siegall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Todd E. Simpson Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Eric L. Dobmeier Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Jean I. Liu J.D. Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Darren S. Cline Executive Vice President - Commercial
Age: 52
Bio & Compensation  - Reuters
Jonathan Drachman M.D. Chief Medical Officer, Executive Vice President - Research and Development
Age: 54
Bio & Compensation  - Reuters
Vaughn B. Himes Executive Vice President - Technical Operations and Process Sciences
Age: 55
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Lead Independent Director
Age: 47
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 60
Bio & Compensation  - Reuters